Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease

被引:12
|
作者
Darci-Maher, Nicholas [1 ,2 ]
Alvarez, Marcus [1 ,2 ]
Arasu, Uma Thanigai [1 ,3 ]
Selvarajan, Ilakya [3 ]
Lee, Seung Hyuk T. [1 ,2 ]
Pan, David Z. [1 ,2 ]
Miao, Zong [1 ,2 ]
Das, Sankha Subhra [1 ,2 ]
Kaminska, Dorota [1 ,2 ,4 ]
Ord, Tiit [3 ]
Benhammou, Jihane N. [5 ,6 ]
Wabitsch, Martin [7 ]
Pisegna, Joseph R. [6 ,8 ]
Mannisto, Ville [9 ,10 ]
Pietilainen, Kirsi H. [11 ,12 ,13 ]
Laakso, Markku [14 ]
Sinsheimer, Janet S. [1 ,2 ,15 ,16 ]
Kaikkonen, Minna U. [3 ]
Pihlajamaki, Jussi [4 ,17 ]
Pajukanta, Paivi [1 ,2 ,18 ,19 ,20 ]
机构
[1] Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Kuopio, Finland
[3] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland
[4] Univ Calif Los Angeles, Div Cardiol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, Vatche & Tamar Manoukian Div Digest Dis & Gastroen, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] VA Greater Los Angeles HCS, Los Angeles, CA USA
[7] Univ Ulm, Dept Pediat & Adolescent Med, Div Pediat Endocrinol & Diabet, Ulm, Germany
[8] Univ Calif Los Angeles, Dept Med & Human Genet Hepatol & Parenteral Nutr, Div Gastroenterol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[9] Univ Eastern Finland, Dept Med, Kuopio, Finland
[10] Kuopio Univ Hosp, Kuopio, Finland
[11] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Obes Res Unit, Helsinki, Finland
[12] Helsinki Univ Hosp, Obes Ctr, Abdominal Ctr, Helsinki, Finland
[13] Univ Helsinki, Helsinki, Finland
[14] Univ Eastern Finland, Kuopio Univ Hosp, Inst Clin Med, Kuopio, Finland
[15] Univ Calif Los Angeles, Dept Biostat, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA
[16] Univ Calif Los Angeles, Dept Computat Med, David Geffen Sch Med, Los Angeles, CA 90095 USA
[17] Kuopio Univ Hosp, Dept Med Endocrinol & Clin Nutr, Kuopio, Finland
[18] Univ Calif Los Angeles, Bioinformat Interdept Program, Los Angeles, CA 90095 USA
[19] Univ Calif Los Angeles, Inst Precis Hlth, David Geffen Sch Med, Los Angeles, CA 90095 USA
[20] Univ Calif Los Angeles, Los Angeles UCLA Gonda Ctr, David Geffen Sch Med, Room 6357B,695Charles E Young Dr South, Los Angeles, CA 90095 USA
来源
EBIOMEDICINE | 2023年 / 92卷
基金
美国国家卫生研究院; 芬兰科学院; 欧洲研究理事会;
关键词
Serum biomarkers; Non-alcoholic fatty liver disease; Obesity; Dual-tissue transcriptomics screening; Liver histology; Adipogenesis; cis regulatory variants; DIET-INDUCED OBESITY; STEATOHEPATITIS; ADIPOGENESIS; INFLAMMATION; ACTIVATION; EXPRESSION; MECHANISM; EXPANSION; RESOURCE; FIBROSIS;
D O I
10.1016/j.ebiom.2023.104620
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Non-alcoholic fatty liver disease (NAFLD) is a fast-growing, underdiagnosed, epidemic. We hypothesise that obesity-related inflammation compromises adipose tissue functions, preventing efficient fat storage, and thus driving ectopic fat accumulation into the liver.Methods To identify adipose-based mechanisms and potential serum biomarker candidates (SBCs) for NAFLD, we utilise dual-tissue RNA-sequencing (RNA-seq) data in adipose tissue and liver, paired with histology-based NAFLD diagnosis, from the same individuals in a cohort of obese individuals. We first scan for genes that are differentially expressed (DE) for NAFLD in obese individuals' subcutaneous adipose tissue but not in their liver; encode proteins secreted to serum; and show preferential adipose expression. Then the identified genes are filtered to key adipose-origin NAFLD genes by best subset analysis, knockdown experiments during human preadipocyte differentiation, recombinant protein treatment experiments in human liver HepG2 cells, and genetic analysis. Findings We discover a set of genes, including 10 SBCs, that may modulate NAFLD pathogenesis by impacting adipose tissue function. Based on best subset analysis, we further follow-up on two SBCs CCDC80 and SOD3 by knockdown in human preadipocytes and subsequent differentiation experiments, which show that they modulate crucial adipogenesis genes, LPL, SREBPF1, and LEP. We also show that treatment of the liver HepG2 cells with the CCDC80 and SOD3 recombinant proteins impacts genes related to steatosis and lipid processing, including PPARA, NFE2L2, and RNF128. Finally, utilizing the adipose NAFLD DE gene cis-regulatory variants associated with serum triglycerides (TGs) in extensive genome-wide association studies (GWASs), we demonstrate a unidirectional effect of serum TGs on NAFLD with Mendelian Randomization (MR) analysis. We also demonstrate that a single SNP regulating one of the SBC genes, rs2845885, produces a significant MR result by itself. This supports the conclusion that genetically regulated adipose expression of the NAFLD DE genes may contribute to NAFLD through changes in serum TG levels. Interpretation Our results from the dual-tissue transcriptomics screening improve the understanding of obesity -related NAFLD by providing a targeted set of 10 adipose tissue-active genes as new serum biomarker candidates for the currently grossly underdiagnosed fatty liver disease.Funding The work was supported by NIH grants R01HG010505 and R01DK132775. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The KOBS study (J. P.) was supported by the Finnish Diabetes Research Foundation, Kuopio University Hospital Project grant (EVO/VTR grants 2005-2019), and the Academy of Finland grant (Contract no. 138006). This study was funded by the European Research Council under the European Union's Horizon 2020 research and innovation program (Grant No. 802825 to M. U. K.). K. H. P. was funded by the Academy of Finland (grant numbers 272376, 266286, 314383, and 335443), the Finnish Medical Foundation, Gyllenberg Foundation, Novo Nordisk Foundation (grant numbers NNF10OC1013354, NNF17OC0027232, and NNF20OC0060547), Finnish Diabetes Research Foundation, Finnish Foundation for Cardiovascular Research, University of Helsinki, and Helsinki University Hospital and Government Research Funds. I. S. was funded by the Instrumentarium Science Foundation. Personal grants to U. T. A. were received from the Matti and Vappu Maukonen Foundation, Ella och Georg Ehrnrooths Stiftelse and the Finnish Foundation for Cardiovascular Research.Copyright & COPY; 2023 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:26
相关论文
共 50 条
  • [31] Adipose tissue-derived stem cells promote the reversion of non-alcoholic fatty liver disease: An in vivo study
    Liao, Naishun
    Pan, Fan
    Wang, Yingchao
    Zheng, Youshi
    Xu, Bo
    Chen, Wenwei
    Gao, Yunzhen
    Cai, Zhixiong
    Liu, Xiaolong
    Liu, Jingfeng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 37 (05) : 1389 - 1396
  • [32] Bioinformatics analysis of ferroptosis-related genes and immune cell infiltration in non-alcoholic fatty liver disease
    Zhang, Huan
    Axinbai, Malina
    Zhao, Yuqing
    Wei, Jiaoyang
    Qu, Tongshuo
    Kong, Jingmin
    He, Yongqiang
    Zhang, Liping
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [33] Expression of immune related genes and possible regulatory mechanisms in different stages of non-alcoholic fatty liver disease
    He, Risheng
    Guan, Canghai
    Zhao, Xudong
    Yu, Liang
    Cui, Yunfu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [34] The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease
    Catalina Atorrasagasti
    Agostina M. Onorato
    Guillermo Mazzolini
    Journal of Physiology and Biochemistry, 2023, 79 : 815 - 831
  • [35] The Impact of Vitamin D in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Patients with Morbid Obesity
    Borges-Canha, Marta
    Neves, Joao Sergio
    Mendonca, Fernando
    Silva, Maria Manuel
    Costa, Claudia
    Cabral, Pedro M.
    Guerreiro, Vanessa
    Lourenco, Rita
    Meira, Patricia
    Salazar, Daniela
    Ferreira, Maria Joao
    Pedro, Jorge
    Leite, Ana Rita
    von-Hafe, Madalena
    Vale, Catarina
    Viana, Sara
    Sande, Ana
    Belo, Sandra
    Lau, Eva
    Freitas, Paula
    Carvalho, Davide
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 487 - 495
  • [36] The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease
    Atorrasagasti, Catalina
    Onorato, Agostina M.
    Mazzolini, Guillermo
    JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2023, 79 (04) : 815 - 831
  • [37] Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis
    Hu, Jianping
    Xu, Yong
    He, Zemin
    Zhang, Hui
    Lian, Xiaoqing
    Zhu, Tiantian
    Liang, Caihong
    Li, Jun
    ONCOTARGET, 2018, 9 (02) : 2752 - 2760
  • [38] Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
    Sohrab Nobarani
    Fariba Alaei-Shahmiri
    Rokhsareh Aghili
    Mojtaba Malek
    Hossein Poustchi
    Maryam Lahouti
    Mohammad E. Khamseh
    Digestive Diseases and Sciences, 2022, 67 : 1389 - 1398
  • [39] Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness
    Sunbul, Murat
    Agirbasli, Mehmet
    Durmus, Erdal
    Kivrak, Tarik
    Akin, Hakan
    Aydin, Yucel
    Ergelen, Rabia
    Yilmaz, Yusuf
    ATHEROSCLEROSIS, 2014, 237 (02) : 490 - 493
  • [40] Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease
    Cimini, Flavia A.
    Barchetta, Ilaria
    Carotti, Simone
    Bertoccini, Laura
    Baroni, Marco G.
    Vespasiani-Gentilucci, Umberto
    Cavallo, Maria-Gisella
    Morini, Sergio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (19) : 3407 - 3417